March-in rights on pricey cancer drug; biotech workers in short supply

Taking stock of the drug industry, from the lab to the medicine chest  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

STAT+: Will the Biden administration approach march-in rights like Trump? Fight over pricey cancer drug offers a test By Ed Silverman Adobe “The fact that NIH is even contemplating march-in is significant," said Robert Cook-Deegan, a professor at Arizona State University. Read More STAT+: Madrigal drug for fatty liver disease clears safety hurdle in first of two late-stage studies By Adam Feuerstein Adobe Madrigal is seeking to be the first company to win approval for a drug to treat NASH — a potentially lucrative commercial opportunity. Read More Moderna wins full approval for its Covid-19 vaccine, as Novavax seeks authorization for its version By Helen Branswell Sergio Flores/Getty Images The development came as Novavax submitted a long-awaited application to the FDA for an emergency use authorization for its vaccine. Read More Sponsor content by STAT Events STAT Event: How biomarkers are changing cancer care The way doctors treat cancer is evolving. On Feb. 2, STAT looks into this by examining how advances in technology are changing the way biomarkers are used. Register here to join the conversation. STAT+: In the heart of the booming biotech industry, workers are in short supply By Anissa Gardizy — Boston Globe David L. Ryan/Boston Globe With every snew company that comes out of stealth mode or a mega-funding round, the people problem has gotten worse. Read More Monday, January 31, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser